Table 2 Comparative analysis of the outcomes between study groups
| Â | DM (n = 425) | New onset DM (n = 384)a | IGT (n = 560)b | IFG (n = 376)c | NGT (n = 782)d |
|---|---|---|---|---|---|
30-day outcome: | |||||
Myocardial infarction – no. (%) | 4 (1.0) | 5 (1.3) | 10 (1.8) | 6 (1.7) | 13 (1.7) |
PCI – no. (%) | 16 (3.7) b | 6 (1.6) | 7 (1.3) | 9 (2.4) | 18 (2.3) |
CABG – no. (%) | 0 (0) | 4 (1.0) d | 4 (0.7) d | 1 (0.3) | 0 (0.0) |
Stroke – no. (%) | 1 (0.2) | 1 (0.3) | 1 (0.2) | 2 (0.5) | 2 (0.3) |
Mortality – no. (%) | 9 (2.1) | 3 (0.8) | 6 (1.0) | 2 (0.5) | 9 (1.1) |
MACE – no. (%) | 28 (6.6) c d | 15 (4.0) | 23 (4.1) | 12 (3.2) | 26 (3.3) |
1-year outcome: | |||||
Myocardial infarction – no. (%) | 63 (14.8) | 42 (11.0) | 86 (15.3) | 59 (15.8) | 106 (13.6) |
PCI – no. (%) | 90 (21.2) b | 72 (18.8) | 86 (15.3) | 70 (18.6) | 129 (16.5) |
CABG – no. (%) | 41 (9.6) | 32 (8.3) | 54 (9.7) | 41 (10.9) | 64 (8.2) |
Stroke – no. (%) | 7 (1.6) | 9 (2.3) d | 8 (1.4) | 5 (1.3) | 5 (0.6) |
Mortality – no. (%) | 38 (9.0) a c d | 20 (5.2) | 38 (6.7) c d | 11 (2.9) b | 29 (3.7) |
MACE – no. (%) | 174 (41.0) a c d | 111 (29.0) b | 208 (37.1) a c d | 113 (30.0) b | 229 (29.3) |
Remote follow up: | |||||
Myocardial infarction – no. (%) | 73 (17.2) | 51 (13.3) | 95 (17.0) | 63 (16.8) | 128 (16.4) |
PCI – no. (%) | 108 (25.4) b | 88 (22.9) | 103 (18.4) | 79 (21.0) | 166 (21.2) |
CABG – no. (%) | 49 (11.5) | 32 (8.3) | 55 (9.9) | 46 (12.2) | 72 (9.2) |
Stroke – no. (%) | 13 (3.1) | 12 (3.1) | 11 (2.0) | 8 (2.1) | 11 (1.4) |
Mortality – no. (%) | 52 (12.3) c d | 37 (9.6) c d | 53 (9.4) c d | 21 (5.6) a b | 50 (6.4) |
MACE – no. (%) | 187 (43.9) | 153 (39.8) | 227 (40.6) | 152 (40.4) | 310 (39.7) |